Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Easywell Biomedicals's enterprise value is NT$3,575.7 Mil.
Easywell Biomedicals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$106.8 Mil. Therefore, Easywell Biomedicals's EV-to-EBITDA for today is 33.48.
The historical rank and industry rank for Easywell Biomedicals's EV-to-EBITDA or its related term are showing as below:
ROCO:1799'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -521.8 Med: -12.61 Max: 751.34
Current: 33.48
During the past 13 years, the highest EV-to-EBITDA of Easywell Biomedicals was 751.34. The lowest was -521.80. And the median was -12.61.
ROCO:1799's EV-to-EBITDA is ranked worse than 82.58% of 729
companies
in the Drug Manufacturers industry
Industry Median: 13.27
vs ROCO:1799: 33.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Easywell Biomedicals's PE Ratio (TTM) for today is calculated as:
Easywell Biomedicals's share price for today is NT$29.35.
Easywell Biomedicals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Easywell Biomedicals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's EV-to-EBITDA falls into.
Easywell Biomedicals's current Enterprise Value is NT$3,575.7 Mil.
Easywell Biomedicals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$106.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easywell Biomedicals (ROCO:1799) has a EV-to-EBITDA of 33.48 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Easywell Biomedicals. According to the industry distribution chart, Easywell Biomedicals ranks #602 out of 729 companies in the Drug Manufacturers industry, placing it in the top 82.6%.
Is Easywell Biomedicals' EV-to-EBITDA too high?
Easywell Biomedicals' current EV-to-EBITDA is 33.48. The Drug Manufacturers industry median EV-to-EBITDA is 13.27. Easywell Biomedicals' value of 33.48 is 152.3% above this industry median. Based on the distribution chart, Easywell Biomedicals ranks #602 out of 729 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Easywell Biomedicals has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #602 out of 729 companies for EV-to-EBITDA. This places Easywell Biomedicals in the lower half of its industry. The industry median EV-to-EBITDA is 13.27. Easywell Biomedicals' value of 33.48 is 152.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.27, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Easywell Biomedicals's current EV-to-EBITDA of 33.48 is 152.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Easywell Biomedicals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current EV-to-EBITDA is 33.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$89.31, compared to a current price of NT$29.35 — trading 67.1% below its estimated fair value. The current EV-to-EBITDA is 33.48 and 152.3% above the Drug Manufacturers industry median of 13.27. Easywell Biomedicals' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current EV-to-EBITDA is 33.48 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$29.35 is trading 67.1% below its estimated GF Value™ of NT$89.31.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
EV-to-EBITDA: 33.48
GF Value™: NT$89.31 vs. price of NT$29.35 (67.1% below fair value)
Industry Position: 152.3% above the Drug Manufacturers median (#602 of 729)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
59GF Score
Get the complete analysis for ROCO:1799
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
